Latest From Jessica Merrill
Rocket's all-stock acquisition of Renovacor is valued at about $53m and adds a preclinical portfolio targeting genetically driven cardiovascular disease.
A Phase IIb trial testing IMC-1 for fibromyalgia failed to reach statistical significance on the primary pain endpoint, but one cohort showed an improvement and Virios intends to pursue the drug further.
Terlivaz is the first product approved to improve kidney function in adults with hepatorenal syndrome (HRS). The approval is a milestone in a long regulatory road for the drug.
The start-up, founded on science from the University of Pennsylvania, announced a $102m series A financing and the appointment of former Silverback CEO Laura Shawver as CEO.
The US drug pricing watch dog issued a final assessment on Amylyx's AMX0035 and Mitsubishi Tanabe's Radicava for ALS.
The company presented positive early data at ESMO for two bispecific antibodies that are important to the company's long-term business strategy, MUC16xCD3 and METxMET.